PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sub	Substitute for form 1449/PTO			Complete If Known		
00-		•		Application Number	Not Yet Assigned Concurrently Herewith	
. 11	NFORMATIC	ON DISC	CLOSURE	Filing Date		
	TATEMENT		•	First Named Inventor	Paul E. Young	
				Art Unit	N/A	
	(use as many	sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	PF383D1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials	Citè No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
11	Ε	LEWIS et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by	
	İ	Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in	
U		Mediating Heregulin Responsiveness," Cancer Res., 56:1457-1465 (Mar. 1996)	
1	F	ZHANG et al., "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that	
1	l	binds and activates ErbB4," PNAS USA, 94:9562-9567 (Sep. 1997)	
	G	HOLMES et al., "Identification of Hereguln, a Specific Activator of p185erbB2,"	
- 1		Science, 256:1205-1210 (May 22, 1992)	
<u> </u>	Н	GEORGE et al., "Macromolecular Sequencing and Synthesis: Selected Methods and	
	1	Application, Schlesinger, D.H. (eds.), Alan R. Liss, Inc., New York, NY, pp. 127-149	
1		(1988)	١.
	1	WILSON, R.K., "The WashU-Merck EST Project," GenBank Accession No. H50042	
		(Sep. 18, 1995)	
	j	WILSON, R.K., "The WashU-Merck EST Project," GenBank Accession No. H49100	
		(Sep. 18, 1995)	
	К	WILSON, R.K., "The WashU-Merck EST Project," GenBank Accessoin No. H23651	Γ
-1	1	(Jul. 6, 1995)	
	L	CULOUSCOU et al., "Characterization of a breast cancer cell differentiation factor	Γ
- 1	ļ —	that specifically activates the HER4/P180ERB4 receptor," J. Biol. Chem.,	
<u> </u>		268(25):18407-18410 (1993)	L
	М	GARRAWAY et al., "Neuregulin-2, a new ligand of Erb3/Erb4-receptor tyrosine	
1		kinase," Nature, 387:512-516 (1997)	
	N	GASSMANN et al. "Aberrant neural and cardiac development in mice lacking the	
1	'`	ErB4 neuregulin receptor," Nature, 378(6555):390-394 (1995)	
	0	HIJAZI et al. "NRG-3 in human breast cancers: Activation of multiple erbB family	Γ
	1	proteins," Int'l. J. Oncology, 13(5):1061-1067 (1998)	١
	P	LAVERRIERE et al. "GATA-4/5/6, a subfamily of three transcription factors	
	1	transcribed in developing heart and gut," J. Biol. Chem., 269(37):23177-23184	ļ
1		(1994)	
	Q	PLUMB et al., "Human DNA sequence from clone RP1-185K11," Database EMBL	Γ
	-	'Online' Accession No. AL136085 (Jan. 7, 2000)	
	R	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino	Γ
l l	``	Acid Substitutions," Science, 247:1306-1310 (1990)	
	S	LAZAR et al., "Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and	Γ
(~	Leuine 48 Results in Different Biological Activities," Molec. and Cell. Biol., 8:1247-	1
1_	1	1252 (1988)	۱

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature Signature	Date Considered	7.25.05

^{&#}x27;Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/0Ba/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sut	Substitute for form 1449/PTO			Complete if Known		
300				Application Number	Not Yet Assigned	
IN	NFORMATIO	N DIS	SCLOSURE	Filing Date	Concurrently Herewith	
	TATEMENT			First Named Inventor	Paul E. Young	
				Art Unit	N/A	
	(use as many s	sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	PF383D1	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (il known)	Publication Date MM-DD-YYYY	Name of Patentee or 'Applicant of Cited Document,	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
M	A	US-6,096,871	08-01-2000	Presta et al.			
1	В	US-6,121,415-B1	09-19-2000	Godowski et al.			
	C	US-6,252,051-B1	06-26-2001	Godowski et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear			
150	D	WO-99/02681-A9	01-21-1999	Genentech, Inc.		L		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Out			,	Application Number	Not Yet Assigned	
11	VFORMATION	N DI	SCLOSURE	Filing Date	Concurrently Herewith	
S	TATEMENT	BY /	APPLICANT	First Named Inventor	Paul E. Young	
				Art Unit	N/A	
	(use as many sh	neets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	PF383D1	

SA		BURGESS et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>J. Cell. Biol.</i> , 111:2129-2138 (1990)			
I	ט	BORK, P., "Powers and the pitfalls in sequence analysis," Genome Res., 10:398-400 (2000)			

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.